WallStreetZenWallStreetZen

NASDAQ: LAB
Standard Biotools Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Standard Biotools revenue was $86.26M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2026) ending on Mar 31, 2026 was $21.1M, down 11.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LAB annual revenue was $85.3M, with -6.2% growth year-over-year.

LAB past revenue growth

How has LAB's revenue growth performed historically?

Company
-3.71%
Industry
9.99%
Market
34.88%
LAB's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LAB's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LAB's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

LAB revenue history

Current Revenue
$86.3M
Current Earnings
$78.2M
Current Profit Margin
90.7%

Be the first to know when LAB announces revenue.

LAB Revenue History By Year

LAB Yearly RevenueLAB RevenueLAB ChangeLAB Revenue Growth
2025-12-31$85.33M-$5.68M-6.24%
2024-12-31$91.01M-$15.33M-14.42%
2023-12-31$106.34M$8.39M+8.57%
2022-12-31$97.95M-$32.63M-24.99%
2021-12-31$130.58M-$7.56M-5.47%
2020-12-31$138.14M$20.90M+17.83%
2019-12-31$117.24M$4.28M+3.79%
2018-12-31$112.96M$11.03M+10.82%
2017-12-31$101.94M-$2.51M-2.40%
2016-12-31$104.45M-$10.27M-8.95%
2015-12-31$114.71M-$1.74M-1.50%
2014-12-31$116.46M$45.27M+63.60%
2013-12-31$71.18M$18.85M+36.02%
2012-12-31$52.33M$9.47M+22.09%
2011-12-31$42.87M$9.31M+27.73%
2010-12-31$33.56M$8.15M+32.06%
2009-12-31$25.41M$10.07M+65.58%
2008-12-27$15.35M$8.07M+110.96%
2007-12-29$7.28MN/AN/A

1 of 2

Standard Biotools Revenue FAQ

What was LAB's revenue last quarter?

On Invalid Date, Standard Biotools (NASDAQ: LAB) reported Q1 2026 revenue of $21.15 million up 4.57% year over year. In the same quarter last year, Standard Biotools's revenue was $20.22 million.

What was Standard Biotools's revenue in 2025?

Standard Biotools's annual revenue for the twelve months ending Dec 31, 2025 was $85.33 million, a 6.24% decrease year over year.

How much does Standard Biotools make in a day?

Based on Standard Biotools annual revenue for the past five years, LAB makes an average of $280,113.97 per day.

What was Standard Biotools's annual revenue growth in the past year?

As of Q2 2026, Standard Biotools's revenue has grown -3.71% year over year. This is 13.7 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 9.99%. Standard Biotools's revenue in the past year totaled $86.26 million.

How much does Standard Biotools make in a year?

Standard Biotools's revenue by year for the past five years is:
  • Standard Biotools's revenue for the twelve months ending Dec 31, 2025 was $85.33 million, a 6.24% decrease year over year.
  • Standard Biotools's annual revenue for Dec 31, 2024 was $91.01 million, a 14.42% decrease from 2023.
  • Standard Biotools's annual revenue for 2023 was $106.34 million, a 8.57% increase from 2022.
  • Standard Biotools's annual revenue for 2022 was $97.95 million, a 24.99% decrease from 2021.
  • Standard Biotools's annual revenue for 2021 was $130.58 million, a 5.47% decrease from 2020.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.